Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Therapy for Acute Otitis Media
NCT00000363Phase 3Completed
- Sponsor
- National Institute on Deafness and Other Communication Disorders
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of chlorpheniramine and prednisolone in acute otitis media (AOM) (4 arms), sponsored by National Institute on Deafness and Other Communication Disorders. Primary endpoints: Rate of treatment failure at 2 weeks, Duration of middle ear effusion at 3 months and 1 more. Status: completed.
02
Drugs
chlorpheniramineprednisolone
03
Conditions
acute otitis media (AOM)
Beyond the preview
Go deeper on NCT00000363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000363.